Silence Therapeutics plc (SLN) Initiated at Overweight as Analyst Highlights siRNA Pipeline Potential We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts.
Silence Therapeutics plc (NASDAQ:SLN) is one of the most promising stocks on our list
TheFly reported on June 24 that Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of SLN with an Overweight rating and no price target. The firm highlighted Silence as a clinical-stage biotechnology company developing siRNA-based therapies targeting hematologic, cardiometabolic, and rare diseases. Cantor identified divesiran as a key catalyst, with Phase 2 polycythemia vera data expected in August.
The firm expressed confidence in the upcoming results, expecting Divesiran to potentially demonstrate strong efficacy with dosing advantages. Cantor views Silence as undervalued at its current market capitalization of approximately $300 million, with its valuation analysis suggesting more than 160% potential upside and an attractive risk-reward profile ahead of the clinical update. On June 11, Silence Therapeutics plc (NASDAQ:SLN) presented follow-up and quality-of-life findings from the Phase 1 SANRECO study evaluating divesiran, an siRNA therapy targeting TMPRSS6, in 21 patients with polycythemia vera who required phlebotomy.